Sheryl Zayas
Family Medicine · Wilton Manors, FLNPI 1598034167
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 67.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $13,209 and has fallen 87.4% since, to $1,658 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 536 payments — averaging $44.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$16K
- Viiv Healthcare Company$4K
- Johnson & Johnson$1K
- Merck$341
- Indivior Inc.$332
- Theratechnologies Inc.$288
- plus $1K from 21 others
Across 2 payments — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$9K
What the payments were for
- Speaking & faculty fees$12,07051%
- Travel & lodging$9914%
- Food & beverage$10,60245%
- Education$1281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 144 | $16,096 |
| Viiv Healthcare Company | 190 | $4,002 |
| Johnson & Johnson(2 entities) | 89 | $1,293 |
| Merck | 19 | $341 |
| Indivior Inc. | 14 | $332 |
| Theratechnologies Inc. | 10 | $288 |
| Orexo US, Inc. | 16 | $264 |
| EMD Serono, Inc. | 13 | $258 |
| MDD US Operations, LLC | 3 | $144 |
| AbbVie | 7 | $137 |
| Braeburn Inc. | 6 | $101 |
| Janssen Products, LP | 1 | $100 |
| GSK | 4 | $64 |
| Astellas Pharma US Inc | 2 | $55 |
| AstraZeneca | 3 | $47 |
| Napo Pharmaceuticals Inc | 2 | $38 |
| Amgen | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Lilly USA, LLC | 2 | $29 |
| Alkermes, Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,791 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 137 | $541,984 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 78 | $317,497 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 49 | $290,199 |
| TivicayDolutegravir Sodium | 56 | $174,042 |
| DescovyEmtricitabine/Tenofov Alafenam | 56 | $129,096 |
| DovatoDolutegravir Sodium/Lamivudine | 29 | $88,047 |
| JulucaDolutegravir/Rilpivirine | 14 | $43,837 |
| PrezcobixDarunavir/Cobicistat | 17 | $41,182 |
| PifeltroDoravirine | 19 | $32,835 |
| JardianceEmpagliflozin | 15 | $10,671 |
| Testosterone | 21 | $6,427 |
| Estradiol Valerate | 20 | $2,432 |
| Acyclovir | 19 | $1,832 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,809 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $1,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $16,096 | $988,576271 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Juluca | $4,002 | $305,92699 claims |
| Janssen Products, LPSymtuza | $100 | $290,19949 claims |
| Johnson & JohnsonPrezcobix | $1,293 | $41,18217 claims |
| MerckPifeltro | $341 | $32,83519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Wilton Manors
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.